PT-141 mastery course
Unit 5 of 11

The RECONNECT trials

The entire FDA approval rests on the RECONNECT program: two pre-specified, identically designed Phase 3 trials in preme…

What two Phase 3 trials actually showed, effect sizes and all

The entire FDA approval rests on the RECONNECT program: two pre-specified, identically designed Phase 3 trials in premenopausal women with HSDD. This is the strongest evidence PT-141 has, and it deserves an honest reading.

The unit walks the diagnostic target, the dose-finding that preceded it, the co-primary endpoints, and the two most important honesty points: the effect sizes are modest, and the satisfying-sexual-events endpoint did not separate from placebo.

Key terms

The disorder being treated


Choosing the 1.75 mg dose


How the trials were built


The co-primary endpoints


Statistically real, clinically modest


The endpoint that did not separate